Advanced Oncotherapy Share Discussion Threads

[makeamillion1] 28/9/2018 07:18

Half Year Report published:

hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/x8ne3ox

Hopefully setting up for a good day!

[justjill] 27/9/2018 16:26

Surprised it hasn't been a better day. After the next update in a few days, which surely must also be positive(?) then we should see more director buying, plus others.

Certainly this is a milestone - proven treatment, albeit small scale, and still with long walk ahead. But should provide a huge boost for the "sales team".

Definitely strongly pointing forward now.

[marvin66] 27/9/2018 12:16

Yes, buys coming in!

[daijavu] 27/9/2018 12:05

I actually bought some today

[daijavu] 27/9/2018 12:04

There is a fair amount of buying today so perhaps the share price might move.

[daijavu] 27/9/2018 08:24

I read the update and so did Mr Market. Mr market has barely flickered an eyelid.
Not yet.

Give it a day or two.

[paul_98] 27/9/2018 08:18

Read the update and more to follow. Cheer up! This is superb.

[daijavu] 27/9/2018 08:10

boom?

What boom?

[paul_98] 27/9/2018 07:50

As guessed boom!!!

[makeamillion1] 27/9/2018 07:20

ADVANCED ONCOTHERAPY PLC
(“Advanced Oncotherapy” or the “Company”;)

Technological update

Key technological milestone completed on schedule
LIGHT system now generating proton beams with energies required to treat superficial tumours

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, provides an update on the technological development of its LIGHT system.

The Company announces that it has reached a key milestone in the development of its next-generation proton therapy technology, the LIGHT system. The first system under development at the Company’s testing facility at CERN, Geneva is now generating a proton beam with sufficient energy required for treating some superficial tumours.

Superficial tumours include ocular tumours, parotid gland tumours, basal cell carcinoma, and some soft tissue sarcomas, to name a few. A specific type of basal cell carcinoma, known as periocular tumours, was modelled for the purpose of establishing the treatment plan based on the data and the proton acceleration reached with the LIGHT system. Periocular tumours are challenging to treat because of their proximity to the eye. Protons may offer an advantage for these patients by largely sparing the eyes and eye lenses from radiation dose.

The resulting plan is available on the website of the company and ‑ based on the proton acceleration generated ‑ shows that:
· The current LIGHT system comfortably covers the simulated clinical case, as well as some marginally deeper tumours
· The healthy tissue ‑ such as the eye and the lens ‑ is dramatically spared from radiation dose with a steep decrease of the radiation levels directly next to the tumour site
· The lens dose is well controlled and the radiation dose around the optic nerve is near zero
The Treatment Planning Software (“TPS”) used in the LIGHT system has been developed by AVO’s partner, RaySearch AB and will be further tailored to include LIGHT system’s many advanced features for AVO’s proprietary use.

The LIGHT system is designed to elicit significant advantages over existing proton therapy technology, such as a higher beam precision and targeting which results in a more conformal dose and greater adjustability at source. Furthermore, the accelerator varies the beam energy actively and therefore significantly reduces undesired secondary radiation seen in traditional proton therapy systems. This ‑ together with the modular design of the LIGHT system ‑ result in thinner radiation shielding next to the accelerator and a smaller foot-print. This makes the LIGHT systems easier and cheaper to operate and install in city-centre locations as compared to systems currently on the market. Taken altogether, these features make the LIGHT system the ideal tool for making proton therapy systems more widely available, with a technology expected to be capable of providing improved outcomes and reduced treatment related side effects.

Having reached this milestone on schedule the development team are now focussed on the relatively low-execution risk activity of adding further accelerating modules with the objective of treating all indications suitable for proton therapy. A further technical update will be provided in the next few days.

Commenting, Nicolas Sérandour, CEO of Advanced Oncotherapy, said: “We are delighted to have achieved this key milestone in the development of our first LIGHT system. I am also very proud of our team and thankful for their dedication in achieving this milestone. This announcement marks the shift from a complex ‑ albeit well-proven ‑ scientific and physics reality into a medical application with tangible and direct implications for patients. This very important step supports the confidence we have in delivering our plan and being in a position to offer a system that delivers a better outcome for patients whilst generating more value for the operators.”

[makeamillion1] 27/9/2018 07:14

hxxps://polaris.brighterir.com/public/advanced_oncotherapy/news/rns/story/w063jpw

First major milestone achieved now watch these rise....GLA

[paul_98] 24/9/2018 21:48

Fingers crossed.

[daijavu] 24/9/2018 21:33

paul. All I can say is that I hope you are right but I've been there, done that and I'm still waiting for that promised announcement two years after we were promised it.
All we got was a totally revised development schedule instead of the promised announcement that the development was complete.

As I said, I hope you are right and they keep their word this time.

[paul_98] 22/9/2018 10:30

It’s certainly been very quiet but this gives me strong hope that they are preparing the details for an RNS we know is due by the end of Q3.

[daijavu] 13/9/2018 07:37

It looks as if Liquid Harmony are placing themselves to take the company over. I hope they pay a premium. You long term holders deserve it.

[paul_98] 12/9/2018 15:36

I’m so excited by the expected news! GLA

[paul_98] 12/9/2018 08:56

The risks are far less substantial now.

[daijavu] 12/9/2018 08:51

Very true paul. But some risks are bigger than others. imho, in the case of AVO the risks are substantial and the rewards could be a lot smaller than you think and take a long time to come.

Nevertheless, I might well buy shares in whichever company owns LIGHT when it eventually comes to market. It might even be AVO. Who knows.

[paul_98] 12/9/2018 08:32

News within the next few weeks will prove crucial. I’ve stayed in for big gains. No risk no reward. :-)

[daijavu] 12/9/2018 08:18

Good luck to you too. I managed to recover as well.

I've invested some of my pot in the likes of Bunzl and GAW with a punt in SOS.

I'm wary of the market too. For the same reasons. I think there could be a correction any time within the next six months. It's building up.

[twirl] 11/9/2018 10:18

Hi daijavu

Yes I have recovered somewhat sharewise after losing so much here - by sticking to AIM Co,s with visible revenue streams and divi's. eg PTSG GYM GMAA

I really hope the tech works but would only invest a small part of my pot in this.

Generally though I am wary of the market and uninvested anticipating a significant debt fuelled correction.

Good luck

[daijavu] 11/9/2018 00:38

Hi Twirl. Long time no speak. I see you are still keeping an eye on this one as well.

If it wasn't for the BoD, I might have put my hand in my pocket by now. I have dipped in once or twice since the 'glory days' but it's still too dodgy for a permanent presence, imho. The trouble is that they keep repeating the same old story:

'Nearly there. Everything on track. Shed loads of money coming in. New Directors. Multiple contracts in China, etc.'

I just hope for the sake of the newbies that it is true this time. That it won't all vanish into the mist again.

[casablanca4] 10/9/2018 20:58

hxxps://www.channel4.com/news/proton-beam-cancer-therapy-to-be-available-on-nhs